Chikungunya Virus VLP (E1 E2 C Protein), Recombinant, Mammalian
Catalog No : USB-353218
1090.84€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Chikungunya Virus VLP (E1 E2 C Protein), Recombinant, Mammalian | ||
|---|---|---|---|
| Catalog No | USB-353218 | ||
| Supplier’s Catalog No | 353218 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, 293 human cells | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~90% (SDS-PAGE) | ||
| Form | Supplied as a liquid in 20mM Tris-HCl, pH 7.5, 125mM sodium chloride. May contain traces of sucrose. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | ~90% (SDS-PAGE) | ||
| Description | Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and whilst they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others. Chikungunya virus is a member of the genus Alphavirus in the family Togaviridae. Chikungunya fever is a mosquito-borne disease first identified in Tanzania in 1953. Since 2004 there have been extensive outbreaks in Africa and Asia, and in 2013 the first cases were identified in the Caribbean, and by September 2014 more than 650,000 cases had been reported in the Americas. Chikungunya fever usually starts 2-4 days after chikungunya virus infection, with clinical symptoms including high fever, rash, headache, vomiting, myalgia, and severe joint pain. Because the virus is transmitted by the same mosquitos that transmit Dengue Virus and Zika Virus, and the clinical symptoms of infection with the viruses are also similar, it is important to be able to distinguish diagnostically between the different infections. Because the use of aspirin and other NSAIDs can increase the risk of haemmorhage in Dengue fever, patients should be treated as having Dengue fever until a diagnosis of Dengue fever has been excluded. Source: Recombinant protein corresponding to Chikungunya Virus VLP, constructed from E1, E2 and C proteins, expressed in 293 human cells. Strain: Senegal 37997 Storage and Stability: Aliquot to avoid repeated freezing and thawing and store at -70°C. Stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. | ||
Product Details
© 2020 Imugex All Rights Reserved